PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Participate in the 4th Annual Guggenheim Boston Healthcare Conference

GAITHERSBURG, Md., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in the 4th Annual Guggenheim Boston Healthcare Conference.

Conference details are as follows:

Date: Tuesday, December 13, 2016
Location: Intercontinental Boston Hotel, Boston, MA

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:

Novavax, Inc.Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations

ir@novavax.com 
240-268-2000
              
Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271

Primary Logo

Novavax, Inc.